Hematology

The US Food and Drug Administration has approved a booster dose of the Pfizer-BioNTech COVID-19 vaccine in certain patient populations.

The US Food and Drug Administration has approved the first biosimilar treatment option for the leading cause of vision impairment in older adults, among other eye diseases and conditions.

After an in-depth analysis and review of the data, the US Food and Drug Administration has fully approved the first COVID-19 vaccine for individuals aged 16 years or older.

The US Food and Drug Administration has approved the first treatment option for idiopathic hypersomnia, a chronic sleep disorder.

The FDA has approved a new option for the treatment of patients with late-onset Pompe disease aged 1 year or older.

The US Food and Drug Administration has approved the first of its kind interchangeable biosimilar insulin product for the treatment of diabetes.

In this video, Phil Lempert discusses the recent US Food and Drug Administration approval of a new chronic weight management medication for adults with obesity or overweight.

The US Food and Drug Administration has approved a new asparaginase component for the treatment of a common pediatric and adult cancer.

The US Food and Drug Administration has approved the first oral option for the treatment of children aged 3 months to less than 12 years of age with venous thromboembolism following treatment with...

The US Food and Drug Administration has approved a new generic option for the control of serum phosphorus levels in patients with chronic kidney disease who are undergoing dialysis.